1. Home
  2. PAVM vs PPBT Comparison

PAVM vs PPBT Comparison

Compare PAVM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAVmed Inc.

PAVM

PAVmed Inc.

HOLD

Current Price

$0.29

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.70

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAVM
PPBT
Founded
2014
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
6.5M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
PAVM
PPBT
Price
$0.29
$0.70
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
272.8K
731.3K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$450.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.53
52 Week High
$0.90
$5.20

Technical Indicators

Market Signals
Indicator
PAVM
PPBT
Relative Strength Index (RSI) 39.68 42.65
Support Level $0.27 $0.67
Resistance Level $0.31 $0.87
Average True Range (ATR) 0.02 0.05
MACD -0.00 -0.01
Stochastic Oscillator 17.97 17.54

Price Performance

Historical Comparison
PAVM
PPBT

About PAVM PAVmed Inc.

PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: